Chemotaxins C5a and fMLP induce release of calprotectin (leucocyte L1 protein) from polymorphonuclear cells in vitro

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 3, 1998, Pages 143-148

  Hetland, G ^a,c   Talgo G J ^b   Fagerhol, M K ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Calprotectin; Chemotaxins; Neutrophil granulocyte

Indexed keywords

CALPROTECTIN; COMPLEMENT COMPONENT C5A; FORMYLMETHIONYLLEUCYLPHENYLALANINE; IODINE 125;

ARTICLE; CELLULAR IMMUNITY; CHEMOTAXIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0031925721     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.3.143     Document Type: Article

References (40)

1. Fagerhol MK, Dale I, Andersson T. Release and quantitation of a leukocyte derived protein (L1). Scand J Haematol 1980;24:393-8.
2. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem 1983;143:1-6.
3. Dale I, Brandzaeg P, Fagerhol MK, et al. (1985) Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Am J Clin Pathol 1985;84:24-34.
4. Steinbakk M, Næss-Andresen C-F, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763-5.
5. Sohnle PG, Collins-Lech C, Wiessner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis 1991;164:137-42.
6. Miyasaki KT, Bodeau AL, Murthy JH, et al. In vitro antimicrobial activity of the human neutrophil cytosolic S-100 protein complex, calprotectin, against Capnocytophaga sputigena. J Dental Res 1993;72:517-23.
7. Sander J, Fagerhol MK, Bakken JS, et al. Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein. Scand J Clin Lab Invest 1984;44:357-62.
8. Berntzen HB, Fagerhol MK, Østensen M, et al. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 1991;18: 133-8.
9. Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989;16:1416-20.
10. Chenoweth DE, Hugli TE. Demonstration of a specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978;75:3943-7.
11. Haviland DL, McCoy RL, Whitehead WT, et al. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 1995;154:1861-9.
12. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991;349:614-17.
13. 125I-chemotactic peptide by human neutrophils. J Biol Chem 1979;254:10700-6.
14. Sozzani S, Sallusto F, Luini W, et al. Migration of dendritic cells in response to formylpeptides, C5a, and a distinct set of chemokines. J Immunol 1995;155:3292-5.
15. Feltner DE, Smith RH, Marasco WA. Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4 chemotaxis receptors. J Immunol 1986;137:1961-70.
16. Webster RO, Zanolari B, Henson PM. Neutrophil chemotaxis in response to surface-bound C5a. Exp Cell Res 1981; 129:55-62.
17. McPhail LC, Snyderman R. Activation of the respiratory burst enzyme in human polymorphonuclear leukocytes by chemoattractants and other soluble stimuli. Evidence that the same oxidase is activated by different transductional mechanisms. J Clin Invest 1983;72:192-200.
18. Becker EL, Showell HJ, Henson PM, et al. The ability of chemotactic factors to induce lysosomal enzyme release. I. The characteristics of the release, the importance of surfaces and the relation of enzyme release to chemotactic responsiveness. J Immunol 1974;112:2047-54.
19. Damerau BE, Grunefeld H, Vogt W. Aggregation of leukocytes induced by the complement-derived peptides C3a and C5a and by three synthetic formyl-methionyl peptides. Int Arch Allergy Appl Immunol 1980;63:159-61.
20. Hetland G, Berntzen HB, Fagerhol MK. Levels of calprotectin (leukocyte L1 protein) during apheresis. Scand J Clin Lab Invest 1992;52:479-82.
21. Hetland G, Mollnes TE, Garred P. Activation of complement during apheresis. Clin Exp Med 1991;84:535-8.
22. Garred P, Fosse E, Fagerhol MK, et al. Calprotectin and complement activation during major operations with or without cardiopulmonary bypass. Ann Thorac Surg 1993; 55:649-59.
23. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968;21(suppl 97):77-89.
24. Hetland G, del Zoppo GJ, Mori H, et al. Uptake of C5a by polymorphonuclear leukocytes (PMNs) after focal cerebral ischemia. I. Effect of tirilazad mesylate intervention on C5a uptake by PMNs. Immunopharmacology 1994;27:191-8.
25. Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in faeces. A methodological study. Scand J Gastroenterol 1992;27:793-8.
26. Fagerhol MK. Nomenclature of proteins: is calprotectin a proper name for the elusive myelomonocytic protein? J Clin Pathol: Mol Pathol 1996;49:M74-9.
27. Brandtzaeg P, Jones DB, Flavell DJ, et al. Mac 387 antibody and detection of formalin resistant myelomonocytic L1 antigen. J Clin Pathol 1988;41:963-70.
28. Bergh K, Iversen OJ. Production of monoclonal antibodies against the human anaphylatoxin C5a desArg and their application in the neoepitope-specific-sandwich-ELISA for the quantification of C5a des Arg in plasma. J Immunol Methods 1992;152:79-87.
29. Hetland G, Moen O, Bergh K, et al. Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo. Ann Thorac Surg 1997;63:1076-80.
30. Day AR, Pinon D, Muthukumaraswarny N, et al. Synthesis of several chemotactic peptide antagonists. Peptides 1980;1: 289-91.
31. Levin J, Bang FB. The role of endotoxin in the extracellular coagulation of limulus blood. Bull John Hopkins Hosp 1964; 115:265-74.
32. Duff GW, Atkins K. The inhibitory effect of polymyxin B on endotoxin-induced endogenous pyrogen production. J Immunol Meth 1982;52;333-40.
33. Chenoweth DE, Goodman MG. The C5a receptor of neutrophils and macrophages. Agents Actions 1983;12(suppl): 252-73.
34. Prossnitz ER, Quehenberger O, Cochrane CG, et al. Signal transducing properties of N-formyl peptide receptor expressed in undifferentiated HL60 cells. J Immunol 1993; 151:5704-15.
35. Ember JA, Sanderson SD, Hugh TE, et al. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol 1994;144:393-403.
36. Dahinden C, Galanos C, Fehr J. Granulocyte activation by endotoxin. I. Correlation between adherence and other granulocyte functions, and role of endotoxin structure on biologic activity. J Immunol 1983;130:857-62.
37. Mollnes TE, Garred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1988;73:484-8.
38. Burwinkel F, Roth J, Goebeler M, et al. Ultrastructural localization of the S-100-like proteins MRP8 and MRP14 in monocytes is calcium-dependent. Histochemistry 1994; 101:113-20.
39. Santhanagopalan V, Hahn BL, Dunn BE, et al. Antimicrobial activity of calprotectin isolated from human empyema fluid supernatants. Clin Immunol Immunopathol 1995;76: 285-00.
40. Sohnle P, Collins-Lech O, Wiessner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis 1991;164:137-42.